Clinical Trial Update: Study of SNX-5422 in TP53 Null Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial of SNX-5422 in TP53-null cancers was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-11-14